AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16433210 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietaria depot extract at 25 BU/mL (1.5 microg/mL Par j 1)
Number of subjects: 42
Study 16433210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12575905 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-FAT diet (50 % fat, >34 % monounsaturated fatty acids)
Number of subjects: 17
Study 12575905 — intervention group
Group type: EXPERIMENTAL
Intervention: SUCROSE diet (high carbohydrate increase of 90 g sucrose/d)
Number of subjects: 17
Study 12575905 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-GI diet (high-carbohydrate, high-GI)
Number of subjects: 17
Study 12575905 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-GI diet (high-carbohydrate, low-GI)
Number of subjects: 17
Study 10656230 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing sulphonylurea dosages
Number of subjects: 174
Study 10656230 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding metformin
Number of subjects: 174
Study 8876776 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 0
Study 8876776 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (2,000 IU/day)
Number of subjects: 0
Study 8876776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1464539 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Episode Approach (IEA) workshops
Number of subjects: 0
Study 1464539 — intervention group
Group type: COMPARATOR
Intervention: Traditional comparative information workshops
Number of subjects: 0
Study 3882509 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids
Number of subjects: 22
Study 3882509 — intervention group
Group type: COMPARATOR
Intervention: Casein
Number of subjects: 22
Study 30133940 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation during reminiscence practice, bi-weekly for eight sessions
Number of subjects: 72
Study 30133940 — intervention group
Group type: COMPARATOR
Intervention: No olfactory stimulation during reminiscence practice
Number of subjects: 72
Study 27676156 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Honey Supplementation (70g, ninety minutes before each training session)
Number of subjects: 24
Study 27676156 — intervention group
Group type: COMPARATOR
Intervention: Exercise (Control)
Number of subjects: 24
Study 24941816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/(kg x h)
Number of subjects: 100
Study 24941816 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 0.5 mg/(kg x h)
Number of subjects: 100
Study 24941816 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 22156910 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational board game
Number of subjects: 180
Study 22156910 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (health talk)
Number of subjects: 180
Study 20621660 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg OpunDia
Number of subjects: 29
Study 20621660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 19061694 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 18000
Study 19061694 — intervention group
Group type: COMPARATOR
Intervention: simvastatin monotherapy 40 mg
Number of subjects: 18000
Study 16195202 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological awareness therapy (12 hours of therapy)
Number of subjects: 20
Study 16195202 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study 12391494 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous prednisone in combination with intramuscular polyvitaminic therapy (group A)
Number of subjects: 62
Study 12391494 — intervention group
Group type: COMPARATOR
Intervention: Polyvitaminic therapy alone (group B)
Number of subjects: 62
Study 10216057 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular hole group
Number of subjects: 10
Study 10216057 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 7818255 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (7.5 mg) oral methotrexate
Number of subjects: 60
Study 7818255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2363111 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium monofluorophosphate with calcium salts (100 mg disodium monofluorophosphate, 500 mg calcium)
Number of subjects: 12
Study 2363111 — intervention group
Group type: COMPARATOR
Intervention: Control preparation (not specified)
Number of subjects: 12
Study 145441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mithramycin (15 micrograms per kilogram of body weight per day)
Number of subjects: 27
Study 145441 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin combined with mithramycin
Number of subjects: 27
Study 145441 — intervention group
Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 27
Study 31904874 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible distal‐chip laryngoscopy (FDL)
Number of subjects: 23
Study 31904874 — intervention group
Group type: COMPARATOR
Intervention: Rigid telescopic laryngoscopy (RTL)
Number of subjects: 23
Study 31904874 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' assessment of discomfort for FDL
Number of subjects: 23
Study 31904874 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference between FDL and RTL
Number of subjects: 23
Study 30748011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (6-year group)
Number of subjects: 910
Study 30748011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (3-year group)
Number of subjects: 910
Study 30748011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 910
Study 30748011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate addition after anastrozole
Number of subjects: 910
Study 30748011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates after anastrozole cessation
Number of subjects: 910
Study 30748011 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 910
Study 28734759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study.
Number of subjects: 74
Study 25887365 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological multidisciplinary face-to-face treatment program (6 weeks, 7 group sessions)
Number of subjects: 147
Study 25887365 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based treatment program (6 weeks, 2 group sessions + 4 telephone contacts)
Number of subjects: 147
Study 25887365 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological multidisciplinary face-to-face treatment program
Number of subjects: 147
Study 25887365 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based treatment program
Number of subjects: 147
Study 24395994 — intervention group
Group type: EXPERIMENTAL
Intervention: General lifestyle content (Tx1)
Number of subjects: 1698
Study 24395994 — intervention group
Group type: EXPERIMENTAL
Intervention: Personally tailored health information (Tx2)
Number of subjects: 1698
Study 24395994 — intervention group
Group type: EXPERIMENTAL
Intervention: Personally tailored health information plus online video-based peer coaching (Tx3)
Number of subjects: 1698
Study 24395994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (Tx1, Tx2, Tx3)
Number of subjects: 1698
Study 20723799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 to 200 mg/day
Number of subjects: 469
Study 20723799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 20723799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 469
Study 18959553 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational advertisement regarding disease symptoms
Number of subjects: 413
Study 18959553 — intervention group
Group type: COMPARATOR
Intervention: NZ direct-to-consumer advertisements (DTCA)
Number of subjects: 413
Study 18959553 — intervention group
Group type: COMPARATOR
Intervention: Other Australian advertisements
Number of subjects: 413
Study 18959553 — intervention group
Group type: COMPARATOR
Intervention: Emotive and transformational advertisements
Number of subjects: 413
Study 15845716 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior popliteal approach (Group 1)
Number of subjects: 120
Study 15845716 — intervention group
Group type: COMPARATOR
Intervention: Labat's approach (Group 2)
Number of subjects: 120
Study 15845716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 120
Study 12810178 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 80
Study 12810178 — intervention group
Group type: COMPARATOR
Intervention: Control (nonusers of HRT)
Number of subjects: 80
Study 10554734 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessing centralized databases for zipcode-level income information
Number of subjects: 0
Study 10554734 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of participating center in the 'stroke belt' (southeastern United States)
Number of subjects: 0
Study 10554734 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic patterns analysis
Number of subjects: 0
Study 9093645 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 100 micrograms/kg (Group DS)
Number of subjects: 16
Study 9093645 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil anesthesia (Group S)
Number of subjects: 16
Study 1746459 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 1 year using the Canadian Airforce plan for physical fitness
Number of subjects: 40
Study 1746459 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 6757621 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated phosphatidyl choline therapy (3 g/day)
Number of subjects: 15
Study 6757621 — intervention group
Group type: COMPARATOR
Intervention: Normal maintenance immunosuppressive therapy
Number of subjects: 15
Study 28888762 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium longum, 90 billion colony-forming units per day)
Number of subjects: 46
Study 28888762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26259908 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini in vitro fertilization (single embryo transfer)
Number of subjects: 564
Study 26259908 — intervention group
Group type: COMPARATOR
Intervention: Conventional in vitro fertilization (double embryo transfer)
Number of subjects: 564
Study 26259908 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini in vitro fertilization
Number of subjects: 564
Study 26259908 — intervention group
Group type: COMPARATOR
Intervention: Conventional in vitro fertilization
Number of subjects: 564
Study 24099432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) group
Number of subjects: 378
Study 24099432 — intervention group
Group type: COMPARATOR
Intervention: CB bibliotherapy
Number of subjects: 378
Study 24099432 — intervention group
Group type: COMPARATOR
Intervention: Brochure control
Number of subjects: 378
Study 22893167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral conjoint therapy for PTSD (15 sessions)
Number of subjects: 80
Study 22893167 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 80
Study 19922797 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI statin therapy
Number of subjects: 2979
Study 18612008 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross‐linked, e‐beamed, melted polyethylene
Number of subjects: 0
Study 18612008 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene sterilized by gamma irradiation in air
Number of subjects: 0
Study 16914473 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier treatment with peripheral retinal ablation
Number of subjects: 339
Study 16914473 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 339
Study 12822837 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouping of trials (Block 1 vs Block 2)
Number of subjects: 0
Study 10639356 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (TEC) 400 mg in 100 ml of saline as a 5‐min infusion into a foot vein of the leg to be operated on, administered immediately after the tourniquet was inflated to 400 mm Hg.
Number of subjects: 160
Study 10639356 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (TEC) administered for bilateral TKR, with regional administration repeated for the second knee operation.
Number of subjects: 160
Study 10639356 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (TEC) administered in monolateral and bilateral TKR.
Number of subjects: 160
Study 8895288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 60
Study 8895288 — intervention group
Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 60
Study 8895288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium after neostigmine
Number of subjects: 60
Study 8895288 — intervention group
Group type: COMPARATOR
Intervention: Atracurium after neostigmine
Number of subjects: 60
Study 1906399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 1906399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol (1200 mg/day)
Number of subjects: 34
Study 1906399 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1300 mg/day)
Number of subjects: 34
Study 6614965 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% 5-fluorouracil (5-FU) ointment applied topically for four weeks
Number of subjects: 0
Study 30234853 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Eye (SE) after ERM surgery
Number of subjects: 20
Study 30234853 — intervention group
Group type: COMPARATOR
Intervention: Fellow Eye (FE) as control
Number of subjects: 20
Study 29957615 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccines
Number of subjects: 0
Study 29957615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination approaches in nonhuman primates
Number of subjects: 0
Study 27257003 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training once daily 5 days/week for 2 weeks in addition to usual care
Number of subjects: 70
Study 27257003 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 70
Study 27257003 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 70
Study 24574902 — intervention group
Group type: EXPERIMENTAL
Intervention: Single education and counseling intervention (45-minute session 48 hours before HSG)
Number of subjects: 217
Study 24574902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 217
Study 22191426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17β‐estradiol in smokers
Number of subjects: 244
Study 22191426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17β‐estradiol in non-smokers
Number of subjects: 244
Study 22191426 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen group (1 mg 17β‐estradiol)
Number of subjects: 244
Study 22191426 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 244
Study 20668840 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.05 mg/kg
Number of subjects: 72
Study 20668840 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.1 mg/kg
Number of subjects: 72
Study 20668840 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.15 mg/kg
Number of subjects: 72
Study 20668840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 18001879 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 10 mg (HY) with alcohol 0.8 g/kg (AL)
Number of subjects: 33
Study 18001879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 25 mg (CE) with alcohol 0.8 g/kg (AL)
Number of subjects: 33
Study 18001879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 33
Study 18001879 — intervention group
Group type: COMPARATOR
Intervention: Alcohol 0.8 g/kg (AL)
Number of subjects: 33
Study 16708806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (1 x 10(4) U/kg intravenously before CPB and added to primary solution)
Number of subjects: 30
Study 16708806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 30
Study 16708806 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study 12562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic arnica 30C
Number of subjects: 64
Study 12562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic arnica 6C
Number of subjects: 64
Study 12562974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10319783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 24
Study 10319783 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 24
Study 8946663 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 6
Study 8946663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 6
Study 8946663 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 6
Study 1773412 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL of ioversol 320 (16 g iodine)
Number of subjects: 100
Study 1773412 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mL of ioversol 320 (24 g iodine)
Number of subjects: 100
Study 1773412 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of iohexol 240 (24 g iodine)
Number of subjects: 100
Study 1773412 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of iohexol 300 (30 g iodine)
Number of subjects: 100
Study 1773412 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mL of iohexol 240 (36 g iodine)
Number of subjects: 100
Study 1773412 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion from the study
Number of subjects: 100
Study 6182834 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐Tubocurarine
Number of subjects: 105
Study 6182834 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine
Number of subjects: 105
Study 6182834 — intervention group
Group type: COMPARATOR
Intervention: alcuroium
Number of subjects: 105
Study 6182834 — intervention group
Group type: COMPARATOR
Intervention: gallamine
Number of subjects: 105
Study 6182834 — intervention group
Group type: COMPARATOR
Intervention: pancuronium
Number of subjects: 105
Study 31350646 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) administered to 676 patients (82.7%)
Number of subjects: 817
Study 31350646 — intervention group
Group type: COMPARATOR
Intervention: No Radiotherapy (RT) administered to 141 patients (17.3%)
Number of subjects: 817
Study 31350646 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 817
Study 30535218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (600 mg daily)
Number of subjects: 30
Study 30535218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30535218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 30
Study 26935138 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 KKW
Number of subjects: 330
Study 26935138 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 KKW
Number of subjects: 330
Study 26935138 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 KKW
Number of subjects: 330
Study 26935138 — intervention group
Group type: EXPERIMENTAL
Intervention: CWL
Number of subjects: 330
Study 26935138 — intervention group
Group type: EXPERIMENTAL
Intervention: MWL
Number of subjects: 330
Study 26935138 — intervention group
Group type: COMPARATOR
Intervention: Neither
Number of subjects: 330
Study 26935138 — intervention group
Group type: EXPERIMENTAL
Intervention: CWL and MWL
Number of subjects: 330
Study 24935072 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor 90 mg bid
Number of subjects: 139
Study 24935072 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor 45 mg bid
Number of subjects: 139
Study 24935072 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel 75 mg qd
Number of subjects: 139
Study 23264238 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 4144
Study 23264238 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation treatment
Number of subjects: 4144
Study 23264238 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 4144
Study 19601492 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:2500 phenylephrine
Number of subjects: 60
Study 19601492 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100,000 adrenaline
Number of subjects: 60
Study 19601492 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 60
Study 17452542 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 20084
Study 15302800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg) daily for 6 months
Number of subjects: 35
Study 15302800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11967252 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib, 200 mg twice daily (n=91)
Number of subjects: 178
Study 11967252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=87)
Number of subjects: 178
Study 9718249 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 0
Study 9718249 — intervention group
Group type: COMPARATOR
Intervention: Attentional focus manipulation
Number of subjects: 0
Study 7654493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg)
Number of subjects: 26
Study 7654493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2668979 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 50 mg capsules
Number of subjects: 40